IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a prominent player in the animal diagnostics industry. The company specializes in providing veterinary diagnostics and software, catering to the growing demand for pet healthcare. With competitors like Zoetis and Heska, IDEXX remains a leader in the market, consistently innovating to meet the needs of veterinary professionals.
On February 2, 2026, BTIG set a price target of $800 for IDXX, while the stock was priced at $639.60. This target suggests a potential increase of approximately 25.08%. Despite a recent decrease of $30.86, or -4.60%, the stock's performance remains strong, with a 52-week high of $769.98 and a low of $356.14.
IDEXX's optimistic revenue and profit projections for 2026 are expected to surpass Wall Street estimates. This positive outlook is fueled by the robust demand for pet diagnostics. The company anticipates that the growing need for veterinary services and increased testing per visit will offset any changes in clinic visit trends.
The company's market capitalization is approximately $51.07 billion, reflecting its significant presence in the industry. With a trading volume of 1,016,178 shares, IDXX continues to attract investor interest. The stock's daily range, with a low of $622.71 and a high of $658.75, indicates active trading and investor engagement.
